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Objective: We wanted to investigate the prevalence and causative factors of
extrahepatic arterial blood supply to hepatocellular carcinoma (HCC) at its initial
presentation and during chemoembolization. 
Materials and Methods: Between February 1998 and April 2000, consecutive
479 patients with newly diagnosed HCC were prospectively enrolled into this
study. A total of 1629 sessions of transcatheter arterial chemoembolization
(TACE) were performed in these patients (range: 1 15 sessions; mean: 3.4 ses-
sions) until April 2004. For each TACE procedure, we determined the potential
extrahepatic collateral arteries (ExCAs) depending on the location of the tumor,
and we performed selective angiography of all suspected collaterals that could
supply the tumor. The prevalence of ExCAs and the causative factors were ana-
lyzed. 
Results: At initial presentation, 82 (17%) of these 479 patients showed 108
ExCAs supplying tumors. Univariate analysis showed that tumor size (p < 0.01),
patient age (p = 0.02), a surface location (p < 0.01), and a bare area location (p <
0.01) were significantly associated with the presence of ExCAs. Multiple logistic
regression analysis showed that only tumor size was predictive of ExCA forma-
tion (p < 0.01, odds ratio = 1.737, confidence interval: 1.533 to 1.969). During
repeated TACE sessions, 97 additional ExCAs were detected in 70 (14%)
patients. The cumulative probability of ExCAs in patients with a large tumor ( 5
cm) was significantly higher than that for those patients with a small tumor (< 5
cm) (p < 0.01).
Conclusion: The presence of ExCAs supplying HCC is rather common, and
the tumor size is a significant causative factor for the development of these collat-
eral arteries.
epatocellular carcinoma (HCC) is one of the most common malignant
tumors in East Asia, and its incidence in the United States is increasing
(1). Although surgical resection offers a better curative option than
nonsurgical treatment, approximately 70% to 80% of cases are inoperable because of
associated liver cirrhosis or advanced disease at the time of presentation (2).
Transcatheter arterial chemoembolization (TACE) has been widely used for the
management of unresectable HCC (3, 4). 
The rationale of HCC chemoembolization is based on the fact that the normal liver
parenchyma receives a dual blood supply from the hepatic artery and the portal vein,
but HCC is exclusively supplied by the hepatic artery (5). However, in clinical practice
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Transcatheter Arterial
Chemoembolization of Hepatocellular
Carcinoma: Prevalence and Causative
Factors of Extrahepatic Collateral 
Arteries in 479 Patientswe frequently encounter HCCs supplied by extrahepatic
collateral arteries (ExCAs) even when the hepatic artery is
widely patent (6 8). Moreover, the development of
ExCAs supplying a HCC prohibits effective control of the
tumor by a transcatheter arterial approach such as hepatic
arterial chemoembolization, hepatic arterial infusion
chemotherapy, radiotherapy using radioactive materials
(i.e., I-131-Lipiodol), and possibly intraarterial gene
therapy. Therefore, the presence or absence of an ExCA
supplying a HCC should be an essential consideration
when selecting an optimal treatment method from among
the currently available treatment modalities, e.g., surgical
resection, percutaneous ablation using absolute ethanol or
radiofrequency, or transcatheter arterial management. 
However, there have been no large prospective series
conducted to determine the prevalence and causative
factors of ExCAs supplying HCCs. Thus, we performed
this prospective study to investigate the prevalence and
causative factors of ExCAs supplying HCCs at its initial
presentation and during chemoembolization. 
MATERIALS AND METHODS
Patients
Between February 1998 and April 2000, 733 patients
with newly diagnosed HCC were referred to us for TACE
treatment. We excluded 254 patients from this study
because of a previous history of surgical resection for HCC
(n = 30), a previous history of percutaneous ethanol
injection or radiofrequency ablation (n = 58), previous
TACE procedures that had been performed at other
institutions (n = 40), and/or they had a diffuse type HCC
that the dimensions of which could not be accurately
determined (n = 126). Therefore, a total of 479 patients
were ultimately enrolled in this study. At the time of study
commencement, our study didn’t require institutional
review board approval, but an informed consent was
obtained from all the patients before each TACE session.
Of the 479 study subjects, there were 375 males and 104
females with ages ranging from 19 to 85 years (mean age:
57 years). A total of 1629 sessions of TACE were prospec-
tively performed in these 479 patients (range: 1 15
sessions; mean: 3.4 sessions) until April 2004. A single
TACE session was administered to 201 patients and
repeated sessions of TACE were administered to 278
patients; 110 patients underwent surgical resection after
one (n = 105) or two (n = 5) TACE sessions. At April
2004, 130 patients were being followed up, and 349
patients died or were lost to follow-up. 
Four hundred fifty one of the 479 patients had various
risk factors of HCC, namely, positivity for hepatitis B
surface antigen (n = 364), antibody to hepatitis C virus (n =
52), both hepatitis B surface antigen and antibody to
hepatitis C virus (n = 2), alcoholic liver cirrhosis (n = 23),
or membranous obstruction of the inferior vena cava (n =
10). A diagnosis of HCC was rendered based on the results
of a percutaneous needle biopsy (n = 35), surgical resection
of HCC during follow-up (n = 110), or by the clinical or
laboratory test results (e.g., elevated alpha-fetoprotein
levels and viral markers) in combination with the typical
computed tomographic (CT) and angiographic appearances
and disease progression on the follow-up images (n = 334). 
Methods of Chemoembolization and Follow-up
All patients had enhanced biphasic helical CT scans of
the liver taken before the initial TACE session; the method
used has been described in detail elsewhere (6 11) and it
is only summarized here. The procedure was initially
performed by infusing 2 12 mL of iodized oil (Lipiodol;
Andre Gurbet, Aulnay-sous-Bois, France) and 10 60 mg
of doxorubicin hydrochloride emulsion (Adriamycin RDF;
Ildong Pharmaceutical, Seoul, Korea) until arterial flow
stasis was achieved and/or iodized oil appeared in the
portal branches. If the initial hepatic arterial blockade was
insufficient because of a large sized mass or arterioportal
shunting, then embolization was performed with
absorbable gelatin sponge particles (1 2 mm in diameter;
Gelfoam; Upjohn, Kalamazoo, MI) soaked in a mixture of
4 6 mg of crystalline mitomycin (Mitomycin-C; Kyowa
Hakko Kogyo, Tokyo, Japan) and 10 mL of nonionic
contrast medium. 
Unenhanced CT scanning of the entire liver was
performed 1 3 weeks after TACE to assess the liver for
traces of iodized oil, and enhanced biphasic helical CT was
performed 1 2 weeks before the next TACE session to
assess the efficacy of the previous treatment and to detect
the residual viable tumor or any recurrent tumor.
Although the normal period between the TACE sessions
was 3 months, these repeat sessions were tailored to the
patients’ tolerance to the procedure and the tumor
response. 
Determination of the Presence of Extrahepatic
Collateral Arteries
One of two experienced interventional radiologists
(J.W.C and J.H.P) reviewed the initial and/or follow-up CT
scans, angiograms and  -fetoprotein serum levels, and they
determined whether a primary or recurrent tumor was
possibly being supplied by ExCAs. A primary tumor was
defined as the tumor initially present, and a recurrent
tumor was defined as a distinct tumor that newly appeared
during the follow-up period after TACE.
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were a subcapsular location or exophytic tumor growth, a
peripheral iodized-oil retention defect within the tumor or
a peripherally located portion of viable tumor on a follow-
up CT scan, and hypertrophied ExCAs around the tumor
on CT scan, a persistent elevation of serum  -fetoprotein
level even after successful chemoembolization via the
hepatic arteries, and the presence of a peripheral tumor
staining defect according to hepatic arteriography (6 8,
12 16). In the patients with these suggestive findings, we
localized the ExCAs by the tumor location and we
performed selective angiography on all suspected collater-
als capable of supplying the tumor, i.e., the inferior
phrenic, omental, cystic, adrenal, intercostal, gastric,
internal mammary, superior mesenteric, renal and renal
capsular arteries (6 8, 12 16). When typical tumor
staining was observed by selective angiography of a
suspected vessel, we concluded that the tumor was
supplied by an ExCA (Figs. 1 3). 
When a tumor was located in the bare area of the liver,
we performed selective angiography on the right inferior
phrenic artery and/or the right adrenal artery; when a
tumor was located in the superoanterior portion of the
liver, we performed selective angiography of the internal
mammary artery; when tumor was in contact with the
right kidney, we performed selective angiography of the
right renal artery and right adrenal artery; when tumor
was in contact with omental fat with an exophytic growth
pattern, we performed selective angiography of the gastro-
duodenal artery and of the right and left gastroepiploic
arteries to find the omental branches supplying the tumor;
when a tumor invaded or was in contact with the right
lateral thoracic wall, we performed selective angiography
of the lower intercostal arteries; when an exophytic tumor
was located in the left lateral segment of the liver, we
performed selective angiography of gastric arteries; and
when an exophytic tumor was in contact with the colon,
we performed selective angiography of the colic branch of
the superior mesenteric artery.
If no ExCA was found at an initial TACE session, then
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Fig. 1. A 51-year-old man with hepatocellular carcinoma. 
A. Enhanced CT scan shows enhancing nodular lesion (arrowhead) 2 cm in
size in the liver segment 7.
B. Right hepatic angiogram shows staining of a small nodular tumor (arrow).
C. Right inferior phrenic angiogram shows staining of small nodular tumor
(arrowheads) that are supplied by the right inferior phrenic artery. Note the
staining of the adrenal gland (arrow) that’s supplied by the superior adrenal
artery (open arrow) from the right inferior phrenic artery.
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Fig. 2. A 39-year-old man with hepatocellular carcinoma.
A. Enhanced CT scan shows a large exophytic mass (arrowheads) in the
right liver lobe with prominent vessels (arrows) around the tumor.
B. Celiac angiogram shows a large stained tumor (arrowheads) that’s
supplied by the right hepatic artery and omental branches (arrow) from the
gastroepiploic artery. Note the defect (dotted circle) of tumor staining.
C. Right inferior phrenic angiogram shows tumor staining (arrowheads)
corresponding to the defect on the celiac angiogram.
D. The superior mesenteric angiogram shows that hypertrophied colic branch
(arrow) supply the tumor. Omental branches (arrowheads) supplying the
tumor are also opacified via the pancreaticoduodenal arcade.
E. Gastroepiploic angiogram shows multiple hypertrophied omental branches
(arrowheads) supplying the tumor. Note the tip of the microcatheter (arrow).
CD
Ethe iodized oil distribution in the tumor on the unenhanced
CT performed within three weeks after the initial session
became important for determining the presence or absence
of an ExCA supplying the tumor at its initial presentation.
When a peripheral iodized oil retention defect in tumor
was demonstrated by an unenhanced CT scan and an
ExCA supplying the tumor defect area was found at the
2nd TACE session, we considered that an ExCA was
present at the initial session (7).
Analysis of the Causative Factors of an Extrahepatic
Collateral Supply
We evaluated the following potential causative factors
for the development of ExCAs; the size and location of the
tumor, and the patency of the hepatic artery. Tumors were
assigned to liver segments in accord with Couinaud classifi-
cation (17). If a tumor occupied two or more segments,
then its location was assigned to the dominant segment. In
cases of multinodular tumors, only the largest was
analyzed. Tumor size was defined as the largest tumor
diameter on the transverse CT scans. 
The tumor locations were also classified as surface or
non-surface. If a tumor showed exophytic growth or it was
observed to reach the liver margin on CT, then it was
considered to have a surface location, but if it did not reach
the liver margin, then it was considered to have a non-
surface location. For the subgroups of tumor surface
location, we also tested the hypothesis that a tumor located
in a bare area may have a higher prevalence of ExCAs.
Because the bare area of a liver cannot be clearly outlined,
our operational definition of the bare area of the liver was
the posterior surface of hepatic segment 7 and the
posterior half of the diaphragmatic surface of hepatic
segment 8. If a tumor in the subgroup with a surface
location contacted the bare area, then it was classified as
being located in the bare area, and if not, it was considered
to be in the non-bare area. 
Occlusion of the hepatic artery that was caused by
repeated TACE sessions was defined as the obliteration of
the segmental hepatic arterial branches with a lack of
arterial perfusion in the corresponding liver portion. Celiac
axis occlusion was also recorded when a superior
mesenteric angiogram showed opacification of all the celiac
axis branches. 
Statistical Analysis
Univariate analyses of the correlation of ExCA formation
with several variables (gender, celiac axis occlusion, and a
surface or bare area tumor location) were performed by
using Fisher’s exact test for nominal variables and the t-test
for continuous variables (tumor size and patient age).
Variables with a p value of < 0.25 according to univariate
analysis were chosen as the variables for multiple logistic
regression analysis. For the subgroups of a surface location,
univariate and multivariate analyses were also performed in
the same manner, and univariate analysis was also
performed after stratification by tumor size.
The cumulative probability curves of ExCA formation
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Fig. 3. A 60-year-old man with hepatocellular carcinoma.
A. Enhanced CT scan after six sessions of chemoembolization shows small enhancing tumor (arrowheads) in the liver segment 6. Note
the nodule that has taken up iodized oil (arrow) without viable tumor.
B. Celiac angiogram at the seventh session of chemoembolization shows a small stained tumor (arrow) that’s supplied by an omental
branch (arrowhead) from the gastroduodenal artery. Note attenuation of the hepatic artery (curved arrow) caused by repeated chemoem-
bolization.were drafted using the Kaplan-Meier method and the
results were compared using the log-rank test. Patients lost
to follow-up were censored at the date of last observation.
Patients who underwent surgical resection for HCC after
TACE were censored at the date of the operation. We did
not include data for repeated TACE sessions due to
recurred tumor after surgery in the analysis. P values <
0.05 were considered to indicate statistical significance.
Data processing and analysis were performed using SPSS
version 10.0 (SPSS, Chicago, IL).  
RESULTS
Initial Transcatheter Arterial Chemoembolization
In 82 (17%) of the 479 patients, 108 ExCAs were found
to supply HCCs at the initial TACE session (Table 1). The
numbers of the initial ExCAs per patient were one (n =
61), two (n = 17), three (n = 3), or four (n = 1). Although
celiac occlusion was present in nine (1.9%) patients, the
hepatic artery was widely patent at the initial TACE
session in all the patients. The tumor sizes and locations
are summarized in Table 2. Univariate analysis showed
that tumor size (p < 0.01), patient age (p = 0.02), a surface
location (p < 0.01), and a bare area location (p < 0.01)
were significantly associated with the presence of ExCAs.
Multiple logistic regression analysis showed that only
tumor size was predictive of ExCA formation (p < 0.01,
odds ratio = 1.737, confidence interval: 1.533 to 1.969).
As the tumor size increased, the probability of ExCAs
formation was also increased (Fig. 4). 
In the subgroup of the 349 patients who had tumors with
a surface location, univariate analysis showed that tumor
size (p < 0.01) and a bare area location (p < 0.01) were
significantly associated with the presence of ExCAs.
Multiple logistic regression analysis showed that tumor size
was predictive of ExCA formation (p < 0.01, odds ratio =
1.735, confidence interval; 1.532 to 1.966). After stratifica-
tion by tumor size, a bare area location was not associated
with the presence of ExCAs for tumors less than 10 cm in
diameter (Table 3).
Repeated Transcatheter Arterial Chemoembolization
During repeated TACE sessions for 278 patients, 97
ExCAs were detected at the 2nd to the 15th (mean SD:
5.5 2.7) TACE sessions in 70 (25%) patients (Table 1).
Four of these 70 patients had also ExCAs observed at the
initial TACE session. Therefore, 148 (31%) of the 479
study subjects had ExCAs at the initial or repeat TACE
sessions. In 35 of the above 70 patients, ExCAs supplied
the primary tumors that were present at the initial TACE
session. In the other 35 patients, ExCAs supplied recurrent
tumors. Occlusion of the segmental hepatic artery was
detected in 16 patients during repeated sessions of TACE.
In 12 of these 16 patients, ExCAs were detected at the 4th-
11th TACE sessions.
The cumulative probability curve for the presence of
ExCAs is shown in Figure 5. As the number of TACE
sessions increased, the cumulative probability of ExCAs
also increased, and particularly for those ExCAs supplying
recurrent tumors. The cumulative probability of ExCAs in
patients with a large tumor ( 5 cm) was significantly
higher than that for those patients with a small tumor (< 5
cm) (p < 0.01). Whereas patients who initially had a large
primary tumor usually had ExCAs supplying the primary
tumor, patients with a small tumor usually had ExCAs
supplying a recurrent tumor after several TACE sessions. 
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Table 1. Extrahepatic Collateral Arteries Supplying
Hepatocellular Carcinoma
Extrahepatic Collateral Arteries 
Present at  Detected  Total
Initial during 
TACE Repeated TACE
Right inferior phrenic artery 053 49 102 (49.8)
Omental artery 018 14 032 (15.6)
Cystic artery 007 11 18 (8.8)
Adrenal artery 008 04 12 (5.9)
Intercostal artery 004 07 11 (5.4)
Gastric artery 006 01 07 (3.4)
Right internal mammary artery 002 04 06 (2.9)
Renal or renal capsular artery 003 03 06 (2.9)
Superior mesenteric artery 003 02 05 (2.4)
Left inferior phrenic artery 002 02 04 (2.0)
Periportal collateral vessels 002 00 02 (1.0)
Total 108 97 205
Note. The numbers in parentheses are percentages,
TACE = transcatheter arterial chemoembolization.
Fig. 4. The relationship of the tumor size and the presence of
extrahepatic collateral arteries supplying hepatocellular
carcinoma at the initial transcatheter arterial chemoembolization. 
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Table 2. Characteristics of Tumors at the Initial Transcatheter Arterial Chemoembolization in 479 Patients
Extrahepatic Collateral Arteries at Initial TACE Total P values
Absent Present
Age (mean SD) 57.2 9.8 54.4 10.9 0.020
Gender 0.464
Male 308 67 (18) 375
Female 089 15 (14) 104
Celiac axis occlusion 0.187
Absent 391 79 (17) 470
Present 006 03 (33) 009
Size (mean SD) 3.5 1.9 9.0 4.1 < 0.01
2 cm 112 2 (2) 114
2 4 cm 135 4 (3) 139
4 6 cm 108 11 (9)0 119
6 8 cm 024 15 (38) 039
8 10 cm 015 24 (62) 039
> 10 cm 003 26 (90) 029
Location
Non-surface 130 0 (0) 130 < 0.01
Surface 267 82 (23) 349
Bare area 0000000083 000000000000040 (33) 00000000123 < 0.01
Non-bare area 0000000184 000000000000042 (19) 00000000226
Segment 
S1 005 01 (17) 006
S2 027 03 (10) 030
S3 015 06 (29) 021
S4 035 10 (22) 045
S5 056 07 (11) 063
S6 097 18 (16) 115
S7 029 15 (34) 044
S8 133 22 (14) 155
Note. The numbers in the parentheses are percentages; SD = standard deviation; TACE = transcatheter arterial chemoembolization
Table 3. Relationship Between Tumor Size and the Bare Area for 349 Tumors with a Surface Location
Extrahepatic Collateral Arteries at Initial TACE
Size Bare (n = 123) Non-bare (n = 226) P values Total (n = 349)
Absent Present Absent Present
2 cm 13 1(7) 37 1(3) 0.47 52
2 4 cm 25 1(4) 64 3(4) 1.0 93
4 6 cm 30 3(9) 60 8(12) 1.0 101
6 8 cm 7 6(46) 13 9(41) 1.0 35
8 10 cm 8 8(50) 7 16(70) 0.32 39
> 10 cm 0 21(100) 3 5(63) 0.02 29
Total 83 40(33) 184 42(19) 349
Note. The numbers in parentheses are percentages; TACE = transcatheter arterial chemoembolizationDISCUSSION
For the various strategies to treat hepatic tumors by the
transcatheter arterial approach, knowledge about the
blood supply of hepatic tumors is essential not only for
understanding the strategies’ limitations but also to
develop an adequate protocol to improve their therapeutic
efficacy.
This study describes the prevalence and causes of ExCAs
that supply HCCs. At the initial presentation, 17% of all
tumors and 23% of the tumors in the subcapsular location
or that demonstrated exophytic growth had ExCAs.
In the past literature, most ExCAs were discovered after
the hepatic arterial blood supply had been interrupted by
surgical ligation, repeated embolization or mechanical
injury to the hepatic artery (18 20). However, we found
that almost all the patients with ExCAs had widely patent
hepatic arteries. Among the study population, only nine
patients displayed celiac axis occlusion with patent periph-
eral hepatic arteries. Therefore, hepatic artery occlusion is
not the major cause of developing ExCAs.
In this study, in line with the fact that a surface tumor
location is a prerequisite for the formation of ExCAs, the
most important factor associated with ExCA formation
was the tumor size rather than interruption of the hepatic
artery. Table 2 and Figure 4 clearly show the abrupt
increase in the prevalence of an extrahepatic collateral
supply to HCC with a tumor size in the range of 4-6 cm.
When the tumor was smaller than 4 cm, the prevalence of
ExCA at the initial TACE secession was less than 3% (6 of
253 tumors). Instead, when the tumor was bigger than 6
cm, the prevalence of ExCAs was 63% (65 of 107 tumors).
As the number of TACE sessions increased, the cumula-
tive probability of ExCAs being present also increased
(Fig. 5). For patients with large primary tumors ( 5 cm),
most ExCAs supplied the primary tumor. The increasing
probability of finding ExCAs for large tumors during
repeated TACE procedures can be explained by the
regrowth of invisible tiny tumor foci that were initially
supplied by ExCAs or there was local tumor progression
(i.e., the primary tumor grows to reach a subcapsular
location or it grows exophytically, or it invades an adjacent
organ, resulting in the creation of ExCAs). In contrast, for
the patients with small primary tumors (< 5 cm), most of
the ExCAs supplied the recurrent tumors that developed
after multiple TACE sessions. Peripheral hepatic artery
attenuation or occlusion was frequently associated with
these circumstances. Therefore, the increasing probability
of ExCAs for small tumors during repeated TACE
procedures can be explained by a sequence of events:
peripheral hepatic artery occlusion due to repeated TACE
Chung et al.
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Fig. 5. Cumulative probability curve of the extrahepatic collateral supply.
A. Kaplan-Meier plot shows the cumulative probability curve of extrahepatic collateral arteries supplying all tumors (A) and the primary
tumor only (B).The gap between the two curves means the probability of extrahepatic collateral arteries for recurrent tumors during
repeated TACE sessions.
B. The Kaplan-Meier plot shows the cumulative probability curve of the extrahepatic collateral arteries in patients who all had large
tumors ( 5 cm) (A), primary large tumors (B), all small tumors (< 5 cm) (C), and primary small tumors (D). The cumulative probability of
ExCAs was statistically different between large tumor ( 5 cm, A) and small tumor (< 5 cm, C) (log-rank test, p < 0.01). The gap
between curves A and B stands for the probability of extrahepatic collateral arteries for recurrent tumors in patients with large tumors (
5 cm). The gap between curves C and D represents the probability of extrahepatic collateral arteries for recurrent tumors in patients with
small tumors (< 5 cm).
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eprocedure, the development of ExCAs supplying the
peripheral zone of the liver parenchyma, and then
subsequent remote site tumor recurrence at the peripheral
zone supplied by the ExCAs.
There is a close contact between the liver and the
diaphragm, and the blood supply to the diaphragm can
reach the liver by direct adherence. Thus, the right inferior
phrenic artery is the most common collateral pathway (18).
In our study, the right inferior phrenic artery accounted for
half of all the ExCAs.
It is believed to be likely that ExCAs develop early at
the bare area of the liver because the diaphragm and the
liver are in direct contact without any capsular barrier (18).
We tested the hypothesis that a tumor located in a bare
area may have a higher prevalence of ExCAs. On the
univariate analysis, a tumor located in a bare area had
more ExCAs than did the tumors in a non-bare area.
However, multivariate analysis showed that only tumor
size was associated with ExCA formation. After stratifica-
tion by tumor size, a bare area location was not associated
with the presence of ExCAs for the tumors with a surface
location and also for tumors less than 10 cm in diameter.
This result may be caused by the dominating factor of
tumor size.
Development of ExCAs in HCC is certainly a situation
that limits the efficacy of TACE. Chemoembolization
through ExCAs can be attempted to improve the therapeu-
tic efficacy of TACE. In this situation, special care should
be taken to monitor for ischemic injury to and chemotoxic-
ity in the organs supplied by ExCAs, and selective
catheterization should be accomplished by placing the
catheter tip as close as possible to a specific branch or
branches supplying the neoplasm. Therefore, not every
detected ExCA can be embolized because of failure that is
incurred with performing superselective catheterization or
because of the various TACE-associated complications (8,
9, 21, 22). Acute gastroduodenal mucosal lesions or ulcera-
tions have been described as common TACE complications
(21). When the cystic artery is occluded during TACE, then
gallbladder infarction or cholecystitis can occur (9). Spinal
cord injury has been reported after intercostal arterial
embolization (9). 
There are several retrospective studies that TACE
through ExCAs was useful for preventing tumor progres-
sion (7, 13 16). However, it is not possible to draw any
conclusions as to whether TACE administered in this
manner prolongs the patient’s life-span. Therefore, further
studies are warranted to investigate the survival benefits of
TACE via ExCAs for treating HCC.
Some limitations of the present study should be
mentioned. First, we performed selective angiography of
the ExCAs in patients whom we suspected of having a
blood supply to a tumor. We probably missed unsuspected
ExCAs in some patients. Moreover, in clinical practice,
selective angiography was not performed in some patients
who were at an advanced stage of disease despite our
suspicion about a collateral blood supply. Thus, the
prevalence of ExCAs in this study was probably underesti-
mated. Second, although we showed that the cumulative
probability of ExCAs increased during repeated TACE, we
did not statistically reveal that repeated TACE itself was a
causative factor for the development of ExCAs. Third,
although the attenuation of the hepatic artery is somewhat
subjective to readers, we did not take the attenuation of
the hepatic artery into account when determining the
causative factors of ExCAs. Instead, we took account of
only the occlusion of the segmental hepatic artery, which
was detected in 16 patients during repeated sessions of
TACE. 
In conclusion, the presence of ExCAs supplying HCC is
rather common, and the size of the tumor is a significant
causative factor for the development of these collateral
arteries. 
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